Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

NasdaqGS - Nasdaq Real Time Price USD

PTC Therapeutics, Inc. (PTCT)

Compare

50.02

-0.67

(-1.32%)

At close: February 24 at 4:00:01 PM EST

49.21

-0.81

(-1.62%)

Pre-Market: 5:11:27 AM EST

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks 20 hours ago

PTCT
-1.32%
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 4 days ago

PTCT
-1.32%
EDIT
PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences:

PR Newswire 4 days ago

PTCT
-1.32%
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA). The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of Aug. 19, 2025.

PR Newswire 5 days ago

PTCT
-1.32%
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m. EST.

PR Newswire 11 days ago

PTCT
-1.32%
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year, and Cantor remains most bullish on sepiapterin, an oral precursor to enzymatic cofactor, for phenylketonuri, the analyst tells investors in a research note. The firm says it is “incredibly bullish” around the profile of this drug, which it says offers clear benefits over standard of care KUVAN. Published first o

TipRanks 20 days ago

PTCT
-1.32%
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 21 days ago

PTCT
-1.32%
ALGS
Why PTC Therapeutics (PTCT) Stock Is Rallying Today

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s shares to $113 from $76. Cantor kept an Overweight rating on the name. Why Cantor Is So Bullish on PTCT The bank believes that, in the wake of the results from the Phase 3 trial of […]

Insider Monkey 21 days ago

PTCT
-1.32%
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

PR Newswire last month

PTCT
-1.32%
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the 43rd Annual J.P. Morgan Healthcare Conference today at 11:15 a.m. PST / 2:15 p.m. EST. The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 da

PR Newswire last month

PTCT
-1.32%
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST.

PR Newswire 2 months ago

PTCT
-1.32%
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA).

PR Newswire 2 months ago

PTCT
-1.32%
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.

Investor's Business Daily 2 months ago

PTCT
-1.32%
QURE
-10.59%
PTC Therapeutics price target raised to $71 from $47 at UBS

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is eligible for up to $1.9B in development, regulatory and sales milestones, the analyst tells investors in a research note. PTC is a high conviction call into 2025, where UBS sees PTC a

TipRanks 2 months ago

NVS

NVSEF

PTCT
-1.32%
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.

Zacks 2 months ago

NVS

PTCT
-1.32%
OLMA
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Zacks 2 months ago

PTCT
-1.32%
NVS

SPRO
Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics is set to obtain an upfront payment of $1bn.

Pharmaceutical Technology 2 months ago

NVS

PTCT
-1.32%
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investor's Business Daily 2 months ago

NVS

NVSEF

PTCT
-1.32%
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 2 months ago

PTCT
-1.32%
SNTI

NVS
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. Also Read: FDA Grants Conditional Approval For PTC Therapeut

Benzinga 2 months ago

PTCT
-1.32%
NVS

Performance Overview

Return	PTCT	S&P 500
YTD	+10.81%	+1.73%
1-Year	+84.78%	+17.58%
3-Year	+38.83%	+39.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PTC Therapeutics, Inc. (PTCT)

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Why PTC Therapeutics (PTCT) Stock Is Rallying Today

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Sector Update: Health Care Stocks Slipping Late Afternoon

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

Performance Overview